Payment overview · 2025
General Payments
$1,923.19
113 reported records · 21 companies
Healthcare provider profile · identity verified
Gregory Porter, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SOUTH CHARLESTON, WV · NPI 1053390450
Verified facts
What the public records show
CMS Open Payments records show Gregory Porter, PA received $1,923.19 in general payments during 2025 across 113 reported records.
Novo Nordisk Inc accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Nurtec Odt, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $431.63 | 22.4% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.51 | 10.5% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $187.03 | 9.7% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.52 | 8.1% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $107.06 | 5.6% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $105.17 | 5.5% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $100.72 | 5.2% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $87.64 | 4.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $82.13 | 4.3% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $81.23 | 4.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $61.43 | 3.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54.46 | 2.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.21 | 2.8% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.85 | 2.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $35.08 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.66 | 1.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.17 | 1.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.65 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.05 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.35 | 0.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.64 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,923.19 | 113 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $277.67 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $256.58 | 13 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $188.36 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $187.03 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $134.08 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $133.80 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $119.71 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $107.06 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $105.17 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $102.11 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $94.26 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.28 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $82.13 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $81.23 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.32 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $61.43 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $54.46 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $54.21 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.54 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.86 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.17 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.44 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methylprednisolone | Methylprednisolone | 157 | 133 |
| Azithromycin | Azithromycin | 104 | 95 |
| Lisinopril | Lisinopril | 99 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 31 |
| Atorvastatin Calcium | Atorvastatin Calcium | 78 | 27 |
| Omeprazole | Omeprazole | 77 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 62 | 23 |
| Cefdinir | Cefdinir | 61 | 50 |
| Metformin Hcl | Metformin Hcl | 61 | 22 |
| Furosemide | Furosemide | 60 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 57 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 42 |
| Glimepiride | Glimepiride | 53 | 20 |
| Ozempic | Semaglutide | 53 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 16 |
| Sertraline Hcl | Sertraline Hcl | 48 | 15 |
| Montelukast Sodium | Montelukast Sodium | 45 | 12 |
| Levofloxacin | Levofloxacin | 43 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 16 |
| Simvastatin | Simvastatin | 42 | 14 |
| Amoxicillin | Amoxicillin | 40 | 27 |
| Eliquis | Apixaban | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Losartan Potassium | Losartan Potassium | 34 | 15 |
| Allopurinol | Allopurinol | 33 | suppressed |
| Cephalexin | Cephalexin | 31 | 27 |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 13 |
| Carvedilol | Carvedilol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 13 |
| Finasteride | Finasteride | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 12 |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,923.19 · 113 records | Novo Nordisk Inc | AIRSUPRA, AJOVY, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error